According to the “Re-Start Study,” presented at the 17th European Headache Congress in early December 2023, stopping the use of prescribed an anti-CGRP monoclonal antibody (mAb) for migraine prevention and then restarting the medication could lead to lower efficacy during the second treatment period.
Only roughly one third of patients who took, stopped, and then restarted anti-CGRP mAb achieved the same level of relief as they did on the first course of the medicine. Researchers are now working to determine whether the recommendation should be to continue the medication without interruption, or if the results mean that patients with lower efficacy the second time around are better served by a different medicine.
Read more here.
